PFM Health Sciences’s Myriad Genetics MYGN Stock Holding History

PFM Health Sciences’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-742,138	Closed	-$14.2M	–	93
2022 Q3	$14.2M	Sell	742,138 -435,112	-37%	-$9.98M	0.51%	58
2022 Q2	$21.4M	Sell	1,177,250 -705,107	-37%	-$14.6M	0.82%	46
2022 Q1	$47.4M	Sell	1,882,357 -143,324	-7%	-$3.67M	1.77%	21
2021 Q4	$55.9M	Sell	2,025,681 -847,237	-29%	-$24.5M	1.9%	18
2021 Q3	$92.8M	Sell	2,872,918 -216,234	-7%	-$7.18M	2.73%	9
2021 Q2	$94.5M	Buy	3,089,152 +370,529	+14%	+$10.7M	2.96%	8
2021 Q1	$82.8M	Buy	+2,718,623	New	+$77.2M	2.53%	9
2014 Q2	–	Sell	-40,491	Closed	-$1.38M	–	73
2014 Q1	$1.38M	Sell	40,491 -365,612	-90%	-$11.3M	0.03%	70
2013 Q4	$8.52M	Buy	406,103 +258,727	+176%	+$6.54M	0.17%	53
2013 Q3	$3.46M	Buy	+147,376	New	+$4.19M	0.08%	68

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

PFM Health Sciences's MYGN Position: Q4 2022 in Review

PFM Health Sciences sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 742,138 shares — an estimated $14.2M sold.

PFM Health Sciences first reported a position in MYGN in Q3 2013 and held it in 10 quarters. The position peaked at $94.5M in Q2 2021. 195 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

PFM Health Sciences reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
PFM Health Sciences sold 742,138 Myriad Genetics shares in Q4 2022, an estimated $14.2M.
PFM Health Sciences first reported a position in Myriad Genetics in Q3 2013 and held it in 10 quarters.
PFM Health Sciences's Myriad Genetics position peaked at $94.5M in Q2 2021.
195 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on PFM Health Sciences's 13F filing for Q4 2022, filed 14 Feb 2023.